A Study of EBC-129 in Advanced Solid Tumours
This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours
| Condition(s) | Advanced Solid Tumours |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours |
| Who can participate | Inclusion Criteria: 1. Male or female patients ≥18 years (US) or ≥21 years (Singapore) old 2. Body weight within ≥40 kg - ≤100 kg during Parts A and B, and ≤120 kg during all other parts of the study 3. Demonstrated progression of a locally advanced unresectable or metastatic solid tumour with no alternative standard-of-care therapeutic option with a proven clinical benefit, or are intolerant to these therapies 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 for Part A and 0-1 for Parts B, C and D 5. Hepatic function and adequate renal function, as per protocol standard 6. Adequate bone marrow function as per protocol standard Exclusion Criteria: 1. Unable or not willing to provide tumour tissue sample (from archival tissue or de-novo biopsy) unless if there is a s |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | EDDC (Experimental Drug Development Centre), A*STAR Research Entities |
| Locations | Aurora, Colorado, United States; Houston, Texas, United States; Singapore, South West, Singapore; Singapore, South West, Singapore; Taipei, Taipei, Taiwan |
| Start date | 2023-04-28 |
| NCT ID | NCT05701527 |
| Official listing | https://clinicaltrials.gov/study/NCT05701527 |